References
Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O, Messmore HL, Bakhos M (2008) Rivaroxaban—an oral, direct Factor Xa inhibitor—has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol 143(1):92–99. doi:10.1111/j.1365-2141.2008.07300.x
Than H, Loh JB, Sum CL, Ng HJ (2015) Clinical utility of anti-Xa monitoring and differential sensitivity of prothrombin time assays: an illustrated case report. J Clin Pathol 68(4):318–319. doi:10.1136/jclinpath-2014-202748
Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG (2008) Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 6(8):1304–1312. doi:10.1111/j.1538-7836.2008.03025.x
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Ong, S.Y., Chin, Y.A., Than, H. et al. Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence. Ann Hematol 96, 525–527 (2017). https://doi.org/10.1007/s00277-016-2871-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-016-2871-z